SEC Form 4 · accession 0000919574-18-004000

KIORA PHARMACEUTICALS INC · KPRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

Director · 10% Owner

10% Owner

Director · 10% Owner

Period of report

May 25, 2018

Accepted (ET)

May 30, 2018 · 6:05 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001372514

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	May 25, 2018	P	8,275	$0.5762	A	16,752,500	D
Common Stock^F2	May 25, 2018	P$0	0	$0.00	A	16,752,500	I	See Footnote
Common Stock^F2	May 25, 2018	P$0	0	$0.00	A	16,752,500	I	See Footnote
Common Stock^F1	May 25, 2018	P	9,300	$0.575	A	16,761,800	D
Common Stock^F2	May 25, 2018	P$0	0	$0.00	A	16,761,800	I	See Footnote
Common Stock^F2	May 25, 2018	P$0	0	$0.00	A	16,761,800	I	See Footnote
Common Stock^F1	May 29, 2018	P	40,700	$0.5729	A	16,802,500	D
Common Stock^F2	May 29, 2018	P$0	0	$0.00	A	16,802,500	I	See Footnote
Common Stock^F2	May 29, 2018	P$0	0	$0.00	A	16,802,500	I	See Footnote

No Table II lines on this filing.

F1The reported securities are directly owned by Armistice Capital Master Fund Ltd.
F2The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund Ltd. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.